Clinical trial to investigate efficacy and safety of FE 203799 (GLP-2 analogue) or placebo administered as subcutaneous injections once weekly in two treatment periods followed by FE 203799 once weekly in one treatment period to patients with short bowel syndrome with intestinal failure.

Registry ID

EUCTR2017-002486-21

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG)

Start date

2018-01-18

Completion date

2019-11-21

Last update

2026-08-16

Conditions

• Short Bowel Syndrome (SBS)

Summary

To assess the safety and tolerability of FE 203799 in patients with SBS with intestinal.

Locations

• , , Denmark

Related clinical trials

• A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
• A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
• TED_ORG: Study on Short Bowel Syndrome
• A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

View on source registry